Category: Positron emission tomography

Positron emission tomography (PET) is usually taken as the gold standard for assessment of myocardial viability. A mismatch between perfusion and metabolism whereby underperfused region of myocardium is

Prosthetic valve endocarditis and intracardiac device related endocarditis are difficult to diagnose and treat. Because of dense acoustic shadowing related to the components of prosthetic valves and cardiac

PET CT in aortic disease Positron emission tomography (PET) using fluorodeoxyglucose (FDG) is useful in detecting areas of high metabolic activity as in case of inflammatory cells and

Flurpiridaz, an F-18 based agent for positron emission tomography is all set to revolutionize myocardial perfusion imaging once again.

Metabolic tracers for PET scan include C-11 palmitate, I-123 Beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) and F18 fluro-deoxy glucose (FDG).

Myocardial blood flow (measured by positron emission tomography) during stress divided by resting flow was taken as the coronary flow reserve.

Positron emission tomography (PET) can measure both the myocardial perfusion and metabolism.